HTA Agencies Facing Model Biases: The Case of Type 2 Diabetes

PharmacoEconomics

Volumn 32, Issue 9, 2014, Pages 825-839

  Raimond, Véronique ^a   Josselin, Jean Michel ^b   Rochaix, Lise ^c  

^a Ancien Délégué Général de la Fédération de l'Hospitalisation Privée   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c UNIVERSITÉ PARIS 1 PANTHÉON SORBONNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT;

BIOLOGICAL MODEL; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; ECONOMICS; FRANCE; HUMAN; PRACTICE GUIDELINE; STATISTICAL BIAS;

BIAS (EPIDEMIOLOGY); COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FRANCE; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, BIOLOGICAL; PRACTICE GUIDELINES AS TOPIC; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84939891826     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0172-8     Document Type: Review

References (49)

1. Ricci P, Chantry M, Detournay B, Poutignat N, Kusnik-Joinville O, Raimond V, et al. Coûts des soins remboursés par l’Assurance maladie aux personnes traitées pour diabète. Études Entred 2001 et 2007. BEH. 2001;2009:464–9.
2. Haute Autorité de Santé, Agence nationale de sécurité du médicament et des produits de santé. Stratégie médicamenteuse du contrôle glycémique du diabète de type Recommandations pour la pratique clinique. Saint-Denis La Plaine: HAS; 2013. http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-02/10irp04_reco_diabete_type_pdf.
3. Coyle D, Lee KM, O’Brien BJ. The role of models within economic analysis: focus on type 2 diabetes mellitus. Pharmacoeconomics. 2002;20(Suppl 1):11–9.
4. Asche CV, Hippler SE, Eurich DT. Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus. Pharmacoeconomics. 2014;32(1):15–27.
5. Haute Autorité de Santé. Élaboration de recommandations de bonne pratique. Méthode “Recommandations pour la pratique clinique “. Saint-Denis La Plaine: HAS; 2010 http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-01/guide_methodologique_recommandations_pour_la_pratique_clinique.pdf.
6. National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes. This is an update of NICE clinical guidelines E, F, G and H. NICE clinical guideline 6 London: NICE; 2008. http://www.nice.org.uk/nicemedia/pdf/CG66NICEGuideline.pdf.
7. National Institute for Health and Clinical Excellence. Type 2 diabetes: newer agents. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. This short clinical guideline partially updates NICE clinical guideline 66. The recommendations have been combined with unchanged recommendations from CG66 in NICE clinical guideline 8 London: NICE; 2009. http://www.nice.org.uk/nicemedia/pdf/cg87shortguideline.pdf.
8. Scottish Intercollegiate Guidelines Network, NHS Quality Improvement. Management of diabetes. A national clinical guideline. Edinburgh: SIGN; 2010. http://www.sign.ac.uk/pdf/sign116.pdf.
9. Inspection générale des affaires sociales, Morel A, Lecoq G, Jourdain-Menninger D. Evaluation de la prise en charge du diabète. Tome 1 et 2. Paris: IGAS; 2012. http://www.ladocumentationfrancaise.fr/var/storage/rapports-publics/124000256/0000.pdf.
10. UK Prospective Diabetes Study. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
11. Klarenbach S, Cameron C, Singh S, Ur E. Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. CMAJ. 2011;183:E1213–20.
12. Canadian Agency for Drugs and Technologies in Health. Second-line therapy for patients with diabetes inadequately controlled on metformin: a systematic review and cost-effectiveness analysis. CADTH. Optimal Ther report. 2010;4.
13. Canadian Agency for Drugs and Technologies in Health. Economic evaluation: third-line therapy for patients with type 2 diabetes inadequately controlled with metformin and sulfonylurea combination therapy. CADTH Therapeutic Review. Ottawa: CADTH; 2010.
14. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343:d4169.
15. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.
16. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. The action to Control Cardiovascular Risk in Diabetes Study Group. N Engl J Med. 2008;358:2545–59.
17. Yi Y, Philips Z, Bergman G, Burslem K. Economic models in type 2 diabetes. Curr Med Res Opin. 2010;26:2105–18.
18. Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes. Horm Metab Res. 2009;41:905–9.
19. Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab. 2009;11:804–12.
20. Seino Y, Rasmussen MF, Nishida T, Kaku K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin. 2010;26:1013–22.
21. Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2010;14(36):1–248.
22. National Institute for Health and Clinical Excellence. Liraglutide for the treatment of type 2 diabetes mellitus. NICE technology appraisal guidance 203. London: NICE; 2010. http://www.nice.org.uk/nicemedia/live/13248/51259/51259.pdf.
23. Fakhoury WKH, LeReun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology. 2010;86:44–57.
24. Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2010;20:224–35.
25. Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2009;83:233–40.
26. Barzilai N, Guo H, Mahoney E, Caporossi S, Golm G, Langdon R, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo- controlled trial. Curr Med Res Opin. 2011;27:1049–58.
27. Mohan V, Yang W, Son H, Xu L, Noble L, Langdon RB, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract. 2009;83:106–16.
28. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2011;(10):CD006423.
29. Aschner P, Katzeff HL, Guo H, Sunga S, Williams-Herman D, Kaufman KD, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabestes Obes Metab. 2010;12:252–61.
30. Garber A, Henry R, Ratner R, Garcia-Hernandez P, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel- treatment trial. Lancet. 2009;373:473–81.
31. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.
32. Lee WC, Samyshkin Y, Langer J, Palmer JL. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. J Med Econ. 2012;15(Suppl 2):28–37.
33. Granstrom O, Bergenheim K, McEwan P, Sennfalt K, Henriksson M. Cost-effectiveness of saxagliptin (Onglyza(R)) in type 2 diabetes in Sweden. Prim Care Diabetes. 2012;6(2):127–36.
34. Granström O, Bergenheim K, McEwan P, Sennfält K, Henriksson M. Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden. Prim Care Diabetes. 2012;6:127–36.
35. Canadian Agency for Drugs and Technologies in Health. An economic evaluation of insulin analogues for the treatment of patients with type 1 and type 2 diabetes mellitus in Canada. COMPUS. Optimal Ther Report. 2008;2.
36. Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ. 2009;180:400–7.
37. Brändle M, Azoulay M, Greiner RA. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland. Int J Clin Pharmacol Ther. 2011;49:217–30.
38. Tunis SL, Minshall ME, Conner C, McCormick JI, Kapor J, Yale JF, et al. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis. Curr Med Res Opin. 2009;25:1273–84.
39. Tunis SL, Sauriol L, Minshall ME. Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada. Appl Health Econ Health Policy. 2010;8:267–80.
40. McEwan P, Evans M, Bergenheim K. A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. Diabetes Obes Metab. 2010;12:623–30.
41. Mittendorf T, Smith-Palmer J, Timlin L, Happich M, Goodall G. Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting. Diabetes Obes Metab. 2009;11:1068–79.
42. Brändle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P, Valentine WJ. Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland. Int J Clin Pharmacol Ther. 2009;47:501–15.
43. Haute Autorité de Santé. Efficacité et efficience des hypolipémiants: une analyse centrée sur les statines. Evaluation des technologiques de santé. Evaluation médico-économique. Saint-Denis La Plaine: HAS; 2010. http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-09/5_statines-argumentaire_complet_maj_sept_2010.pdf.
44. Haute Autorité de Santé. Evaluation par classe des médicaments antihypertenseurs. Evaluation des technologiques de santé. Evaluation médico-économique. Saint-Denis La Plaine: HAS; 2013. http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-05/rapport_evaluation_medicaments_antihypertenseurs.pdf.
45. Afzali HA, Karnon J. Addressing the challenge for well informed and consistent reimbursement decisions: the case for reference models. Pharmacoeconomics. 2011;29(10):823–5.
46. Haute Autorité de Santé. Choices in methods for economic evaluation. A methodological guide. Saint-Denis La Plaine: HAS; 2012. http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-10/choices_in_methods_for_economic_evaluation.pdf.
47. Steuten L, van de Wetering G, Groothuis-Oudshoorn K, Retèl V. A systematic and critical review of the evolving methods and applications of value of information in academia and practice. Pharmacoeconomics. 2013;31(1):25–48.
48. Tuffaha HW, Gordon LG, Scuffham PA.J. Value of information analysis in healthcare: a review of principles and applications. Med Econ. 2014 (Epub ahead of print).
49. Siebert U, Rochau U, Claxton K. When is enough evidence enough? Using systematic decision analysis and value-of-information analysis to determine the need for further evidence. Z Evid Fortbild Qual Gesundhwes. 2013;107(9–10):575–84.